Skip to content
type1.science
Phase 1Not yet recruitingNCT06546436

CARC-101C cell therapy in autoimmune T1D

Early-phase study of a single dose of CARC-101C in autoimmune type 1 diabetes; included as a high-uncertainty engineered-cell immunotherapy signal.

Primary endpoints

  • Incidence and severity of adverse events within 3 weeks after administration (NCI CTCAE V5.0).

Results so far

No results posted yet.